000108324 001__ 108324
000108324 005__ 20220511133130.0
000108324 0247_ $$2doi$$a10.1111/jch.14087
000108324 0248_ $$2sideral$$a120971
000108324 037__ $$aART-2020-120971
000108324 041__ $$aeng
000108324 100__ $$aSkapino, E.
000108324 245__ $$aHeight-based equations as screening tools for elevated blood pressure in the SAYCARE study
000108324 260__ $$c2020
000108324 5060_ $$aAccess copy available to the general public$$fUnrestricted
000108324 5203_ $$aThis study evaluated the accuracy of four height-based equations: blood pressure to height ratio (BPHR), modified BPHR (MBPHR), new modified BPHR (NMBPHR), and height-based equations (HBE) for screening elevated BP in children and adolescents in the SAYCARE study. We measured height and BP of 829 children and adolescents from seven South American cities. Receiving operating curves were used to assess formula performance to diagnose elevated BP in comparison to the 2017 clinical guideline. Sensitivity, specificity, and positive and negative predictive values (PPV, NPV) were calculated for the four screening formulas. The diagnostic agreement was evaluated with the kappa coefficient. The HBE equation showed the maximum sensitivity (100%) in children, both for boys and girls, and showed the best performance results, with a very high NPV (>99%) and high PPV (>60%) except for female children (53.8%). In adolescents, the highest sensitivity (100%) was achieved with the NMBPHR for both sexes. Kappa coefficients indicated that HBE had the highest agreement with the gold standard diagnostic method (between 0.70 and 0.75), except for female children (0.57). Simplified methods are friendlier than the percentile gold standard tables. The HBE equation showed better performance than the other formulas in this Latin American pediatric population.
000108324 536__ $$9info:eu-repo/grantAgreement/ES/MICINN-FEDER/GENUD Research Group
000108324 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000108324 590__ $$a3.738$$b2020
000108324 591__ $$aPERIPHERAL VASCULAR DISEASE$$b24 / 65 = 0.369$$c2020$$dQ2$$eT2
000108324 592__ $$a0.909$$b2020
000108324 593__ $$aCardiology and Cardiovascular Medicine$$c2020$$dQ2
000108324 593__ $$aInternal Medicine$$c2020$$dQ2
000108324 593__ $$aEndocrinology, Diabetes and Metabolism$$c2020$$dQ2
000108324 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000108324 700__ $$0(orcid)0000-0002-3850-8235$$aRupérez, A.I.$$uUniversidad de Zaragoza
000108324 700__ $$aRestrepo-Mesa, S.
000108324 700__ $$aAraújo-Moura, K.
000108324 700__ $$aDe Moraes, A.C.
000108324 700__ $$aBarbosa Carvalho, H.
000108324 700__ $$aAristizabal, J.C.
000108324 700__ $$0(orcid)0000-0003-0454-653X$$aMoreno, L.A.$$uUniversidad de Zaragoza
000108324 7102_ $$11006$$2255$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Enfermería
000108324 773__ $$g22, 12 (2020), 2221-2229$$pJOURNAL OF CLINICAL HYPERTENSION$$tJOURNAL OF CLINICAL HYPERTENSION$$x1524-6175
000108324 8564_ $$s347359$$uhttps://zaguan.unizar.es/record/108324/files/texto_completo.pdf$$yPostprint
000108324 8564_ $$s2291020$$uhttps://zaguan.unizar.es/record/108324/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000108324 909CO $$ooai:zaguan.unizar.es:108324$$particulos$$pdriver
000108324 951__ $$a2022-05-11-13:14:01
000108324 980__ $$aARTICLE